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Traumaticbraininjury(TBI)isacomplexdiseaseinthemostcomplexorganofthebody,whosevictimsendurelifelongdebilitating
physical, emotional, and psychosocial consequences. Despite advances in clinical care, there is no eﬀective neuroprotective therapy
for TBI, with almost every compound showing promise experimentally having disappointing results in the clinic. The complex
and highly interrelated innate immune responses govern both the beneﬁcial and deleterious molecular consequences of TBI and
are present as an attractive therapeutic target. This paper discusses the positive, negative, and often conﬂicting roles of the innate
immune response to TBI in both an experimental and clinical settings and highlights recent advances in the search for therapeutic
candidates for the treatment of TBI.
1.Introduction
Traumatic brain injury (TBI) is a leading cause of death
and disability, particularly in young adults who fall victim to
motor vehicle accidents, falls, sporting injuries, and increas-
ingly common assaults. Despite advances in prehospital and
clinical care, a vast majority of severe TBI survivors will not
be able to live independently or return to work [1]. Aside
from the enormous personal burden of TBI, a substantial
economic cost exists, estimated at $8.6 billion dollars each
yearinAustraliaalone[2]whilstintheUnitedStatesthiscost
exceeds $55 billion dollars per year [3].
TBI has been described as the most complex disease in
the most complex organ of the body; a sentiment which
highlights both the multifactorial nature of brain injury in
terms of type and spatial distribution of damage, and the
intricacies of the brain’s responses to insult. The pathology
caused by a TBI can be classiﬁed in two broad temporal
phases: the primary or initial injury to the head, which
cannot be treated or prevented; the secondary injury, which
is instigated by the primary injury, results in a complex
cascade of pathophysiological and neurochemical events [4–
6]. This ongoing secondary injury process is potentially
amenable to intervention and, thus, has been the focus of
research in the past two decades, with a view to halting
or limiting these factors to avoid the progression of initial
injury.
Alas, many compounds showing promise in experimen-
tal models have shown largely disappointing results in the
clinical setting [7, 8], and to date, no eﬀective therapies
exist to treat TBI [4]. This failure is likely due to the afore-
mentioned complexities of the brain, and the propensity
for use of rodents in preclinical trials of compounds, which
overlooks the fundamental diﬀerences between human and
rodent brains. Another key aspect has been the use of
pharmacological agents that target a single factor of the
complexinterconnectedpathwaysleadingtosecondarybrain
damage [9].
The immune system consists of two important com-
ponents: the “innate” system, which is responsible for
immediate, nonspeciﬁc action against pathogens or insults,
and the “adaptive” system, a response tailored to the speciﬁc2 Mediators of Inﬂammation
t h r e a to ri n s u l ta th a n d[ 10]. It is increasingly clear that far
from being distinct, these systems are highly interrelated,
with the innate system shaping and modifying the responses
of the adaptive system [11]. Recently, the role of the innate
immune system has been under the spotlight, as these early
inﬂammatory responses implicitly designed to minimise the
deleterious outcomes of injury have a somewhat paradoxical
role in that they are increasingly implicated in the mediation
of secondary pathogenic cascades.
The central nervous system (CNS) was traditionally
thought to be a site of immune privilege due to the imper-
meable shield of the blood brain barrier (BBB). However,
over the past two decades, it has been well established that
under injury and inﬂammatory conditions, immune cells are
able to cross the BBB and enter the brain parenchyma. The
brainisalsoequippedwithitsownresidentimmunecells,the
microglia,whichundergomarkedrecruitment,proliferation,
and activation in response to virtually any neuropathological
insult [12].
This paper aims to provide an insight into the innate
immune responses elicited by TBI, and the beneﬁcial or
detrimental roles these pivotal responses may exert in the
pathogenesis of brain injury. We will also discuss therapies
and strategies currently under investigation to minimise the
inﬂammatory response to TBI or modulate it to a more
beneﬁcial phenotype.
2.Pathophysiological Responses to
Traumatic Brain Injury
Initial or primary brain injury results in mechanical damage
to the brain as a result of motor vehicle accidents, falls,
sporting injuries, and violence [13]. The complex pathology
caused by the primary TBI is further complicated by the
intrinsic nature of the damage involved: focal or diﬀuse
[5, 14]. Patients with focal injuries often present with
skull fractures and subdural, epidural, or intraparenchymal
haematomas [15], with the damage that occurs being largely
dependent on the site of impact to the head. In contrast,
diﬀuse brain injury is characterised by widespread damage
to the white matter as well as the vasculature caused by
acceleration/deceleration forces to the head [16]. Diﬀuse
injury leads to axonal perturbation and impaired axonal
transport, with gradual axonal disconnection from the soma
[17]. Whilst patients with focal injuries are readily diagnosed
using conventional CT scans, diﬀuse injuries often show no
overt pathology and thus can potentially be missed during
early imaging-assisted diagnosis [1, 7]. In addition, focal and
diﬀuse injuries often coexist, particularly in motor vehicle
accidents, falls, and assaults [5].
Both focal and diﬀuse TBIs can cooccur with insults such
as hypoxia, hypotension and ischemia, or cerebral hypop-
erfusion [18–20]. These insults are commonly reported,
occurring in approximately one-third of severe TBI patients
[21] and are known to exacerbate pathology, with prolonged
cognitive deﬁcits and poorer long-term outcome when
compared to patients experiencing an isolated TBI [22–
25]. Animal studies have further elucidated this observation,
with posttraumatic insults such as hypoxia and hypotension
found to worsen behavioural outcomes and heighten pathol-
ogy in models of both focal and diﬀuse injury [26–33].
At the time of the primary TBI, mechanical damage
to the brain results in the activation of a multitude of
pathways, including (but not limited to) excitotoxicity and
oxidative stress, inﬂux of Ca2+ and Na+,a n de ﬄux of
K+ [34–36]. Subsequently, disruption of cell membranes,
mitochondrial disturbance leading to energy failure, and
a lack of ATP availability hamper reparative mechanisms
the brain may attempt [37, 38]. High intracellular Ca2+
levels also trigger the activation of Ca2+-dependent proteases
including calpains, caspases, and phospholipases, resulting
in damage to the axonal cytoskeleton [39, 40]. Secondary
injury cascades triggered by these primary injurious events
include breakdown of the blood brain barrier (BBB) and
extravasation of vascular ﬂuid into the parenchyma, ulti-
mately culminating in vasogenic oedema [41–43]. Increased
BBB permeability facilitates the inﬁltration of peripheral
immune cells and activation of resident immune cells, which
release chemokines and cytokines and thus perpetuate the
inﬂammatory response in the injured brain, with the end
result of cellular dysfunction and death [44–46].
3.The BloodBrain BarrierAllows
Transient Passage of Immune Cells into
theInjuredBrain
The brain and the CNS have traditionally been considered
to be sites of immunological privilege due to the BBB,
however during certain inﬂammatory states, the BBB allows
the transient passage of immune cells from the vasculature
[47]. The BBB is composed of tight junctions at three sites:
endothelial cells in the cerebral capillaries, the arachnoid
barrier, and the blood-CSF barrier formed by the choroid
plexus[48,49]andisfurtherdeﬁnedbytheassociatedcells—
pericytes and astrocytes [49]. Under normal circumstances,
the BBB tightly controls the exchange between plasma and
the interstitial ﬂuid, however the dysfunction caused by
TBI allows for excess permeability, with disruption of tight
junctions and transcytosis allowing passive diﬀusion. BBB
disruption is typically transient, with an immediate period
of hyperpermeability, in which immune cells and other
products in the plasma may freely cross into the parenchyma
[41, 50]( Figure 1).
4.ExtravasationofImmuneCellsinto
theTraumaticallyInjuredBrain
Though peripheral immune cells may enter the CNS via
the dysregulated BBB, the BBB is open for only limited
periodsoftime,andthuscellsmustalsocrossthevasculature
into the CNS via a process of extravasation. In focal TBI,
neutrophils are the ﬁrst immune cells to enter the injured
brain,appearingﬁrstonthevascularendotheliumwithinthe
ﬁrst 24 hours of injury [51]. The passage of immune cells
through the BBB to the parenchyma is mediated by adhesion
molecules(Figure 1).Thesemolecules,expressedonboththe
vascular endothelium and the immune cells themselves, areMediators of Inﬂammation 3
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Figure 1: Passage of innate immune components through the blood brain barrier (BBB) after TBI. Injury to the brain results in transient
openingoftheBBB,inwhichcomplementproteinsandneutrophilsareabletodirectlyentertheparenchyma.Peripheralmonocytesenterthe
brain through a process of extravasation, in which several adhesion molecules are upregulated in turn on both the monocyte and endothelial
cell to ﬁrst tether, then provide passage for the cell through the BBB. First, constitutively expressed L-selectin binds to upregulated P/E-
selectin on the endothelial cell surface. Once tethered to the endothelium, monocytes are exposed to chemokines that bind to their cognate
receptors on the cell, inducing conformational change and upregulation of β2 integrins, which bind to ICAMsexpressed on endothelial cells.
This ﬁnal interaction between adhesion molecules signals the cell to migrate across the endothelium into the parenchyma, where it begins to
diﬀerentiate and take on the morphology of an activated macrophage. Under the inﬂuence of chemokines, the cell continues the transition
to an activated macrophage state migrates to the site of injury. Figure adapted from [58].
important mediators of brain injury as their expression and
bindinglargelyregulatestheextentofperipheralimmunecell
entrance to the injured brain [52]. These adhesion molecules
are sequentially upregulated to ﬁrst tether, tightly adhere,
and then provide passage for the cell through the vessel
wall, beginning with P- and E-selectin expressed on the
endothelium, whilst L-selectin is constitutively expressed on
leucocytes [53]. Binding of these molecules tethers the cell
to the endothelium, and, once secured, the cell is exposed
to chemokines also present on the endothelium, which are
highly upregulated in response to injury [54]. The binding
of chemokines to their receptors on migratory cells induces
conformationalchangeandsubsequentactivationofthenext
family of adhesion molecules in the sequence, β2 integrins.
These proteins, namely, CD11a (LFA-1), CD11b (Mac-1),
and CD11c (p50.195) are expressed on the leucocyte cell
surface and bind to endothelial cells expressing intercel-
lular adhesion molecules (ICAMs) [52]. ICAMs belong to
the immunoglobulin “superfamily” consisting of ICAM-1,
ICAM-2, and vascular adhesion molecule (VCAM)-1, as
well as ICAM-3, which is expressed on the leucocyte cell
surface [53]. It is this binding which gives the ﬁnal signal for
extravasation of the cell through the endothelium into the
parenchyma.
Inrats,upregulationofE-selectinhasbeendemonstrated
on endothelial cells as early as 4h after weight-drop injury
and remained elevated until 48h [55]. ICAM-1 has also been
shown to be increased on the endothelium after weight-
drop injury 4h post-TBI [55]. In diﬀuse TBI, the number
of ICAM-1 positive vessels was also increased by 4-fold
compared to sham at 24h [46]. This expression pattern
showed late stage ampliﬁcation, with an 8-fold maximal
value observed at 4 days after injury, and only returning to
sham levels 1 week after TBI [46].
Children suﬀering from TBI have also been found
to have increased CSF levels of soluble ICAM-1, which
correlated with poor outcome [56]. In our adult TBI study,
we have reported that patients with large focal contusions
had elevated levels of soluble ICAM-1 in their CSF, whilst
interestingly, patients with small or absent lesions after TBI
showed no such elevations [57]. These diﬀerences likely
reﬂect the inconsistencies seen between distinct forms of
TBI and may be indicative of the reported contrasts in
inﬂammatory cell inﬁltrates in animal studies of focal and4 Mediators of Inﬂammation
diﬀuse brain injuries, which will be discussed in more detail
in the following sections.
5.InnateImmuneCellsin
the Pathogenesis of BrainInjury
The innate cellular response to TBI involves both inﬁltrating
and resident immune cells, which share many functions in
resolving, and at times prolonging the pathological response
to injury [11]. Each cell type involved is brieﬂy discussed
below.
5.1. Inﬁltrating Immune Cells. Neutrophils (often referred
to as polymorphonuclear cells or leukocytes) are bone-
marrow-derived cells which function to phagocytose cellular
debris and bacteria [59]. They produce a number of factors
designed to be harmful to bacteria and other pathogens,
however these substances also have neurotoxic eﬀects on
mammalian cells and their release overtly contributes to
tissue damage [47]. These molecules include reactive oxy-
gen/nitrogenspecies(ROS/RNS),matrixmetalloproteinases,
and proinﬂammatory cytokines that perpetuate damage in
the CNS [37]. After focal TBI, neutrophils are the ﬁrst
immune cell to cross the BBB and enter to sites of injury,
though this response is short-lived, with a peak at 24–48h
after injury and a resolution in neutrophil numbers by 7 days
[60–62]. Interestingly, diﬀuse TBI causes no such inﬁltration
of neutrophils, with only sham-level numbers observed after
injury in both immature and adult rats [46, 63].
Monocytes/macrophages are also bone marrow derived
and contribute to neuroprotection and recovery after CNS
injury by phagocytosing cellular debris and preserving
healthy tissue. These cells have an important function in
antigen presentation to T cells, and as such are also essential
for activation of the adaptive immune response. Acutely
after injury, inﬁltrating macrophages are able to produce
growth factors and neurotrophins such as brain-derived
neurotrophic factor (BDNF), nerve growth factor (NGF),
insulin-like growth factor 1 (IGF1), and anti-inﬂammatory
cytokines such as interleukin (IL)-10 and transforming
growth factor-β (TGF β)[ 64]. However, these cells may
also be neurotoxic to the injured brain, mediating glutamate
release, generating ROS/RNS, and producing chemokines
such as CXCL2, CXCL1, CXCL3, and CXCL8 to induce
migration of neutrophils [65], and CCL-2 and RANTES
to induce migration of monocytes [66]. Activated mono-
cytes/macrophages are also key producers of proinﬂamma-
tory cytokines such as tumor necrosis factor (TNF), IL-
1β, and IL-6 [67]. As with neutrophils, the recruitment of
monocytes is variable between focal and diﬀuse injury types,
with substantially less monocyte recruitment after diﬀuse
injury [51, 68].
5.2. The CNS Resident Innate Immune Cells. Microglia are
the dynamic surveillance cells of the immune system, con-
stantly exploring their environment for noxious agents and
injurious processes [69, 70]. Microglia play a predominant
role in the phagocytosis of cellular debris and respond
to extracellular signals by functional transformation from
a “resting” to an “activated” phenotype, in which their
processes retract, making these cells morphologically and
functionally indistinguishable from macrophages [71, 72].
Activated microglia are highly motile and able to rapidly
move through the brain to sites of injury [70]. Several
neuroinﬂammatory factors are able to stimulate microglial
migration, including the chemokines CCL-2 and fractalkine
[73–75] and complement anaphylatoxin C5a [76]. Microglia
have long been scrutinized for their role in neuronal damage
andparticularlyinsynapticstrippingafterTBI[77],however
it has now been suggested that, rather than being the
perpetrators of neuronal and axonal injury, it is more a case
of “guilt by association,” since microglia may not be active
participants in neuronal damage (for excellent review see
[78]). This hypothesis has been corroborated by in vitro
experiments of rat neuronal and microglial coculture, in
whichevenwhenexposedtoinﬂammatoryfactors,microglia
did not cause direct neuronal damage [74].
Astrocytes are the most numerous cell type in the brain
and become rapidly activated in response to injury in a
process of “reactive astrogliosis,” in which cells undergo
hypertrophyandproliferationproportionaltoinjuryseverity
[79, 80]. The role of astrocytes after TBI is controversial, as
theyareknowntoproducemanyproinﬂammatorycytokines
including TNF, IL-1, and IL-6 and are also major producers
of chemokines [81]. Astrocytes have also been shown to
inhibit axonal spouting in lesioned tissue by formation
of a dense ﬁbrous glial scar [80, 82]. However, this glial
scar also restricts tissue damage by forming a protective
barrier, conﬁning injury to a deﬁned space and preventing
further spread of damage [79, 83]. After TBI, astrocytes
decrease the expression of glutamate transporters, with
reduced glutamate uptake thus intensifying the excitotoxic
response [84]. Conversely, reactive astrocytes upregulate the
expression of matrix metalloproteinase (MMP) after TBI,
and in particular release of MMP-3, which has been shown
to be released from these cells in the vicinity of neurons
undergoing synaptogenesis [85], suggesting that astrocytes
may play a role in the clearance of damaged tissue in order to
make a more permissive environment for neuronal plasticity.
6. Complement ProteinsArePivotalin
the Pathogenesis of TraumaticBrainInjury
Best known for its role in the recognition and elimination
of pathogens, the complement system has recently emerged
as a key innate mediator of the inﬂammatory response after
brain injury. Complement is a complex network of soluble
and cell-associated factors [48] and can be activated through
three diﬀerent pathways depending on the stimulus: the
classical pathway, the alternative pathway, and the lectin
pathway [86]. Within the CNS, complement has been shown
to be upregulated both clinically in TBI patients and in
v a r i o u sm o d e l so fe x p e r i m e n t a lT B I[ 87]. Under normal
physiological conditions, complement proteins are detected
at very low levels in the brain due to the precise com-
partmentalization of the vasculature and the parenchyma
by the BBB [49], and thus peripheral complement proteinsMediators of Inﬂammation 5
are unlikely to enter the brain without disruption of the
BBB. After TBI, the disruption of the BBB allows an inﬂux
of serum complement proteins into the injured CNS [48,
87]( Figure 1). However, complement proteins can also be
producedendogenouslyinthebrainbyastrocytes,microglia,
and neurons in response to infection or injury [48].
Whilst the role of complement is intrinsically one of
elimination and resolution of infection, the inﬁltration
and/or activation of complement proteins after TBI may lead
to inﬂammatory-induced damage by way of C3b deposition
and subsequent opsonisation and phagocytosis, and C5a-
induced recruitment and activation of immune cells from
the periphery, with neutrophils being the “early responders”
[88]. Overt tissue destruction may also occur with the ﬁnal
formation of the membrane attack complex (MAC), the
primary role of which is mechanoporation [86]. Clinically,
elevated levels of two crucial components of the alternative
pathway, C3 and factor B have been demonstrated in the CSF
of severe TBI patients, with concomitant BBB dysfunction
in more than 50% of patients, suggesting that the elevated
levels of C3 and factor B, were due to serum leakage across
the dysfunctional BBB rather than de novo synthesis [89].
Similarly, C5b-9 (MAC), the cytolytic end product of the
complement system has been shown to be increased in the
CSF of TBI patients and was accompanied by a loss of
integrity of the BBB. Interestingly, several patients in this
study experiencing secondary insults such as hypoxemia or
hypoperfusionhadmorepronouncedlevelsofC5b-9intheir
CSF [90].
Complement protein synthesis has also been demon-
strated in the brain after TBI both experimentally and
clinically, with postmortem analysis of human brain tissue
revealing the upregulation of C1q, C3b, C3d, and C5b-9 in
close association with neurons in patients with focal brain
contusions [91]. Experimentally, TBI-induced C3 deposition
has been demonstrated by immunohistochemistry after
lateral ﬂuid percussion TBI [92].
The deleterious role of C5b-9 after TBI has also been
demonstrated experimentally in mice null for the C5b-
9 regulator, CD59. CD59 is able to prevent the forma-
tion of C5b-9 and thus acts as an essential inhibitor of
complement activation and protector from cell death [93].
Consistent with its role, deletion of CD59 led to worsened
neurological outcomes and heightened neuronal cell death,
demonstratingthekeyroleofthecomplementpathwayisthe
pathophysiology of TBI [94]. This detrimental property was
corroborated in transgenic mice overexpressing the soluble
complement inhibitor Crry (complement receptor, related
protein y), which had reduced neurological impairment
and improved BBB dysfunction following TBI compared to
wild type controls [95]. Furthermore, the pathogenesis of
complement activation after TBI has been demonstrated by
dual inhibition of both the classical and alternative pathways
by pretreatment of rats with a soluble complement receptor
type 1 (sCR1) prior to experimental weight-drop TBI. This
dual pharmacological inhibition resulted in a signiﬁcant
decrease in posttraumatic neutrophil inﬁltration, suggesting
that complement activation is an essential mediator of
the early neutrophil inﬂammatory response after TBI [96].
Similarly, experimental TBI using mice deﬁcient for C3 or
the downstream C5, or treatment of wild type mice with
the C5a receptor agonist lessened neutrophil extravasation
a n dr e s u l t e di ns m a l l e rl e s i o n s[ 88]. When C3 was injected
intracerebrally into C3 deﬁcient mice, the extravasation of
neutrophils to the lesion site was ampliﬁed, suggesting that
that locally produced C3 is important in brain inﬂammation
[88].
7.Chemokines MediatePosttraumatic
Neuroinﬂammation andTissue Damage
With the ability to dictate directional migration of neu-
trophils and leukocytes, chemokines are considered essential
mediators of posttraumatic neuroinﬂammation as they con-
trolimmunecelltraﬃckingfromcirculationtoextravasation
[54, 97]. Two main families of chemokines have been
described: CXC and CC. The CXC cytokines, including
CXCL2, CXCL1, CXCL3, and CXCL8, are predominantly
chemoattractant for neutrophils [65], whilst the CC
chemokines CCL-2 (MCP-1) and RANTES attract mono-
cytes and lymphocytes [66]. Additionally, a third class of
chemokines has been implicated in the pathogenesis of brain
injury, the CX3C subfamily, with the only characterised
member being fractalkine (CX3CL1). Fractalkine has the
unique ability to attract both neutrophils and monocytes, as
well as T cells [98].
Clinically, CXCL8 has been found to be acutely elevated
in the CSF and extracellular ﬂuid of patients with severe TBI
and correlated with BBB dysfunction and NGF production
[99, 100]. In paediatric TBI, elevation of CXCL8 strongly
correlated with mortality [101]. Severe TBI patients also
experienced a sustained elevation in levels of CCL-2 for 10
days after injury, though this was highest on days 1 and
2[ 97]. Using cerebral microdialysis, several groups have
recentlydemonstratedacutelyelevatedlevelsofCCL-3,CCL-
4, and RANTES after severe TBI [100, 102]. A prolonged
elevation of fractalkine in the CSF has also been observed
in patients after TBI, with a strong correlation to BBB
dysfunction and corresponding low fractalkine levels in the
serum [103].
Evidence suggests that CXCL1, and particularly CXCL2,
are the key mediators of neutrophil migration early after
focal brain injury, with both CXCL1 and CXCL2 found to
be acutely upregulated within 5h of experimental cortical
impact injury in both mice and rats [61, 104], while after
lateral ﬂuid percussion injury CXCL2 expression has been
shown to peak at 4h in the injured hemisphere [105].
Using mice null for the CXCL2 receptor (CXCR2) in a
cortical impact model, our group demonstrated a signiﬁcant
attenuation in the numbers of neutrophils migrating to the
site of injury as early as 12h after injury, and found that
this correlated with reduced amounts of cell death and tissue
damage [62].
Ample experimental evidence also exists to demonstrate
the presence of monocyte-attracting chemokines acutely
after injury, with elevated mRNA for CCL-2, CCL-4 and
RANTES all observed after experimental cortical injury [97,
106]. By 4h, production of CCL-2 and CCL-4 is signiﬁcantly6 Mediators of Inﬂammation
upregulated both in vivo and in vitro [61, 104, 107], with
levels of CCL-2 peaking between 8 and 12h after injury
[97, 105]. Elevation of these chemokines after both focal
and diﬀuse TBI is strongly correlated with poor functional
outcome [46, 97], with more evidence of this provided
using a CCL-2 knockout mouse for cortical injury, in which
improved neurological function and reduced lesion volume
were attributed to a reduction in macrophage accumulation
[97].
This experimental evidence certainly suggests that
chemokines play a deleterious role in the pathogenesis
of focal brain injury, however their eﬀects in diﬀuse
brain injury are rather diﬀerent, particularly with respect
to CXC (neutrophil-attracting) chemokines. Without the
presence of a gross pathological lesion, very low levels of
CXCL2 have been observed in diﬀuse TBI, correlating with
absent neutrophil migration into the brain [46]. However,
diﬀuse TBI is associated with abundant accumulation of
monocytes/activated microglia in the white matter tracts,
colocalising with axonal pathology [28, 108, 109]. This
cellular inﬁltration/activation also correlates with elevated
CCL-2 levels acutely after diﬀuse injury [46]. So, it appears
that CC chemokines play a more signiﬁcant role in diﬀuse
injury, whilst focal injuries involve both CXC and CC
chemokines. These distinct molecular proﬁles very much
reﬂectindividualmodesofcellularinﬁltrationintheseinjury
subsets.
8.Proinﬂammatory Cytokines Have Dual Roles
inTraumaticBrainInjury
Proinﬂammatory cytokines are produced by several types
of resident CNS cells such as microglia, astrocytes, and
neurons in response to pathological challenge. Cytokines are
usually preformed peptides that are activated by cleavage,
and swiftly released in response to various stimuli. Once
released, cytokines upregulate the expression of cell adhesion
molecules and signal the secretion of chemokines in the early
postinjury period [47], thus stimulating the inﬁltration of
inﬂammatory cells to the injured regions. The activation of
proinﬂammatory cytokines in human and rodent TBI has
been reported since the early 1990s [99, 101, 102, 110–115].
Theirrolewithintheinjuredbrainis,however,oneofduality,
in that they inherently promote repair, but often bring about
additional tissue degeneration by activating a number of
cytotoxic pathways leading to cell death [67]. It appears
that both the timing of proinﬂammatory cytokine release
and their concentrations are critical to ongoing secondary
damage after TBI. The cytokines interleukin IL-1β,T N F ,
IL-6 and granulocyte-colony macrophage stimulating factor
(GM-CSF) have been intensely investigated in a multitude of
human and experimental paradigms to elucidate their role
withintheinjuredbrain(seeTable 1).Eachofthesecytokines
is discussed in more detail below.
9.IL-1
IL-1isknowntoinducemanysignalingpathwaysstimulating
the production of other proinﬂammatory cytokines and thus
is thought to be a key player in initiating the “cytokine cycle”
[136]. IL-1 exists in both membrane-bound (IL-1α)a n d-
secreted (IL-1β) forms, however it is IL-1β that has earned
a reputation as the perpetrator of the acute inﬂammatory
response to TBI. An important distinction is to be made,
however, between IL-1β and other cytokines, in that IL-1β
itself is not directly toxic when produced; rather it is the
propensity to incite other cytokines that lends to its cytotoxic
reputation. In noninjured tissue, IL-1β administration alone
has been demonstrated to have no ill eﬀects [137], however
after TBI IL-1β mRNA is upregulated within minutes, and
increased protein levels are detectable within an hour [110,
138–141]. Clinically, acutely elevated levels of IL-1β have
been detected after injury by microdialysis [100, 102, 117],
in patient CSF [116, 128], and directly in perioperative
and postmortem brain tissue after TBI at both protein
a n dm R N Al e v e l s[ 131, 142]. IL-1β levels have also been
demonstrated to decrease rapidly; in rat models of focal
cortical impact and lateral ﬂuid percussion, IL-1β peaks at
6h post-injury and returns to baseline by 72h [143, 144].
This early and transient rise in IL-1β was also consistent
with our recent ﬁndings in diﬀuse TBI, with a peak in IL-
1β levels at 2h in the cortex of rats subjected to diﬀuse
TBI [27]. When combined with posttraumatic hypoxia,
production of IL-1β was prolonged to 24h, suggesting that
this combinatory insult signiﬁcantly ampliﬁed and sustained
this early inﬂammatory response.
Evidence for the detrimental role of IL-1β is found
in experiments in which its expression is modiﬁed, with
neutralisation of IL-1β in a model of focal TBI in mice
resulting in reduced tissue loss and improved visuospatial
learning [145]. Furthermore, mice null for the IL-1 receptor
(IL-1R1) had decreased VCAM-1 mRNA and a subsequently
reduced extravasation of peripheral macrophages after stab
wound injury. An overall reduction of inﬂammation resulted
in fewer activated microglia and delayed and depressed
expression of cerebral IL-1 and IL-6 [146]. Similarly, block-
age of IL-1β signaling by use of an IL-1 receptor agonist
(IL-1ra) has also been shown to delay the production of
other proinﬂammatory cytokines, reduce cell death, and
improve neurological recovery after experimental focal TBI
and ischaemia [147, 148]. Clinically, endogenous IL-1ra
microdialysate levels in have also been correlated with
improved outcomes in TBI patients [117]. This largely
negative role of IL-1β after injury has also been corroborated
by peripheral administration of IL-1β after TBI, leading to
larger lesions and impaired behavioural outcomes in rats
subjected to ﬂuid percussion injury [118].
10. TNF
Along with IL-1β, TNF has long been thought of as a
cytokine of detriment following injury and still remains a
subject of controversy, particularly as both cytokines have
many signaling cascades in common and share the same
physiologic eﬀects, with the neurotoxic eﬀects of IL-1β
synergistically enhanced in the presence of TNF [149]. TNF
is produced by microglia and astrocytes and its expression
is regulated in an autocrine manner [150]. In TBI patients,Mediators of Inﬂammation 7
Table 1: Key studies highlighting the dual roles of proinﬂammatory cytokines after traumatic brain injury.
(a)
IL-1β
Finding Clinical/experimental Experimental setting Reference
Acutely upregulated after TBI Clinical
Cerebral microdialysis;
adult and pediatric patient
CSF
[100, 102, 116, 117]
Peripheral administration after TBI
results in larger lesions and impaired
behavioural outcomes
Experimental (rat) Fluid percussion injury [118]
Expression exacerbated and prolonged by
secondary insult Experimental (rat) Diﬀuse axonal injury with
posttraumatic hypoxia [27]
Causes BBB dysfunction in vivo Experimental (rat; in vitro) Cerebral endothelial cells [119]
(b)
TNF
Finding Clinical/experimental Study methodology Reference
High levels observed acutely after injury Clinical Cerebral microdialysis,
adult patient CSF N[ 102, 120, 121]
Acutely upregulated in rats after focal TBI Experimental (rat) Controlled cortical injury;
lateral ﬂuid percussion [115, 122]
Administration causes BBB dysfunction
and increased recruitment of peripheral
leukocytes
Experimental (rat,
newborn piglet, rat; in
vitro)
Healthy animals/cerebral
endothelial cells N[ 119, 123, 124]
Inhibition of TNF ameliorates BBB
dysfunction Experimental (rat) Controlled cortical injury [125]
Deﬁciency of TNF/TNF-R causes
exacerbated BBB damage and impairs
long-term recovery
Experimental (mouse) Controlled cortical injury N [126, 127]
Expression exacerbated and prolonged by
secondary insult Experimental (rat) Diﬀuse axonal injury with
posttraumatic hypoxia [27]
(c)
IL-6
Finding Clinical/experimental Study methodology Reference
CSF levels correlate with improved
outcome Clinical Adult and pediatric patient
CSF [128, 129]
Production within 24h localised to
neurons Experimental (rat) Diﬀuse axonal injury [130]
IL-6 deﬁcient mice have heightened
neurodegeneration, increased oxidative
stress, poor behavioural recovery
Experimental (mouse) Controlled cortical injury;
aseptic cerebral injury [158–160]
(d)
GM-CSF
Finding Clinical/experimental Study methodology Reference
Signiﬁcantly upregulated in brain tissue
within minutes of TBI Clinical Postmortem brain tissue [131]8 Mediators of Inﬂammation
(d) Continued.
GM-CSF
Finding Clinical/experimental Study methodology Reference
Promotes neuronal stem cell
diﬀerentiation in vitro Experimental (rat; in vitro) N e u r a ls t e mc e l lc u l t u r e [ 132]
Promotes tissue sparing when
administered in conjunction with IL-3 Experimental (rat) Stab-wound injury [133]
Minimises tissue damage and promotes
behavioural recovery Experimental (rat) Spinal cord contusion [134, 135]
high levels of TNF in the CSF have been observed acutely
after injury [102, 120, 121], although the concentrations
of TNF have been detected at considerably lower levels
compared to other cytokines such as IL-6, TGF-β, and IL-8.
TNF is also upregulated acutely in various experimental rat
models of focal injury [115, 151] and has been ﬁngered as a
key mediator of the inﬂammatory response, with exogenous
TNF administration in healthy brains causing breakdown
down of the BBB and increasing recruitment of peripheral
leukocytes [119, 123, 124]. Consistent with the hypothesised
early detrimental role of TNF in the setting of TBI, its
inhibition resulted in ameliorated BBB dysfunction [125]
and decreased neuronal damage [152]. Whilst most of the
evidence to date has documented the deleterious role of TNF
in brain injury, this is increasingly becoming an issue of
contention, particularly with longer-term studies of TNF-
deﬁcient mice, which showed a robust improvement in
neurological function initially after TBI, but which then
failed to progress in the long term compared to wild type
mice [126]. In addition, TNF-deﬁcient mice have also been
shown to have exacerbated tissue and BBB damage after
TBI [127]. These ﬁndings suggest a key detrimental role
for TNF in the acute phase, but demonstrate that it may
also have a crucial reparative role essential for long-term
recovery. The intrigue of TNF action is not only of its
temporal beneﬁt or detriment, but also in its diﬀerential
expression in focal and diﬀuse brain injuries and species-
speciﬁc expression. Interestingly, the majority of studies
examining TNF expression have used rat focal TBI models,
and we and other groups have not observed any changes
i nT N Fl e v e l si nr a t ss u b j e c t e dt od i ﬀuse TBI [27, 140],
despite the fact that, like focal injuries, diﬀuse TBI evokes
a substantial microglial and astrocytic response. However,
when rats were subjected to diﬀuse TBI with posttraumatic
hypoxia, our group showed a signiﬁcant increase in TNF
levels at 2h, which was maintained until 72h after injury
[27]. In contrast to rat models of focal TBI, in the mouse
closed head injury model we have not observed signiﬁcant
upregulation of TNF at any time examined [61, 97], and it is
becoming increasingly apparent that there may be a species-
speciﬁc production of TNF in CNS pathologies, in that rats
produce more and mice less when subjected to similar levels
of brain damage [153].
11.IL-6
IL-6 is a true pleiotropic cytokine, with roles in both pro-
andanti-inﬂammation,anddeleteriousandbeneﬁcialeﬀects
after TBI [154–156]. However, it is known most often for its
role as an immune stimulator, able to regulate chemokine
production, cell adhesion molecule expression, and enhance
leukocyte recruitment [157]. Clinical studies have indicated
thatIL-6is,forthemostpart,neuroprotective,withmaximal
expression observed two days after injury [102, 112, 116]
and CSF levels correlating with improved outcome in
both children and adults [128, 129]. Previously, we have
demonstrated an increase in IL-6 in the CSF over the ﬁrst
24h after mild experimental diﬀuse TBI, with production of
bothIL-6mRNAandproteinlocalisedtoneurons[130].The
most telling evidence of the beneﬁcial role for IL-6 has come
from studies of IL-6 gene deﬁcient mice, which have been
showntohavepoorbehaviouralrecovery,aswellasincreased
oxidativestress,amorecompromisedimmuneresponse,and
heightened neurodegeneration [158–160].
12.GM-CSF
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) is a hematopoietic cytokine produced by monocytes,
macrophages, and endothelial cells [161], with its receptor
expressed on most cell types in the CNS [162]. GM-CSF has
been shown to have a positive role in promoting neuronal
diﬀerentiation of adult stem cells in vitro [132], though
as one of the least-examined cytokines after TBI, the role
of GM-CSF is still largely to be elucidated. However, GM-
CSF concentrations have been found to be signiﬁcantly
upregulated in human postmortem brain tissue within
minutes of injury [131], indicating that GM-CSF plays an
important role in the acute inﬂammatory response. This
role appears to be one of neuroprotection, with a recent
study employing stab-wound injury in rats observing that
tissue loss was reduced by 40% when rats were administered
a combination of exogenous GM-CSF and IL-3 [133].
Similarly, in models of rat spinal cord injury, rats treated
with GM-CSF had reduced numbers of apoptotic cells and
signiﬁcantly improved neurological function [134]a sw e l la s
reduced glial scar formation, preserved axonal cytoskeleton
integrity,andhighernumbersofregeneratingaxons[135].In
addition, rats exposed to focal cerebral ischemia had smaller
infarct volumes and altered expression of apoptosis-related
genes, with signiﬁcantly increased levels of the antiapoptotic
Bcl-2 and decreased levels of the pro-apoptotic genes Bax
and p53 after treatment with GM-CSF [163]. In a mouse
model of cerebral ischemia, GM-CSF administration alsoMediators of Inﬂammation 9
reduced the infarct size and increased the numbers of circu-
lating blood monocytes/macrophages [164]. Taken together,
thesestudiesindicate thatGM-CSFmayplaya beneﬁcialrole
in neuroprotection, however more studies are required to
clarify its full potential after TBI.
13.Toll-Like Receptors Mediate Innate Immune
Responses to CNS Trauma
The toll-like receptors (TLRs) are a family of pattern recog-
nition receptors which mediate innate immune responses
to diverse pathogen-associated molecular patterns (PAMPs)
[165]. Following injury or neurodegenerative disease with-
out an infectious etiology, the engagement of danger-
associated molecular patterns (DAMPs) by TLRs leads to
exacerbated immune activation and enhanced neuropathol-
ogy [166, 167]. Like all innate immune responses discussed
here, TLR signaling is typically beneﬁcial, yet it has become
increasingly clear that following injury signaling through
TLRs has particularly pathological consequences, contribut-
ing to the activation of microglia and subsequent induction
of NFκB leading to the transcription of proinﬂammatory
mediators [168, 169]. Microglia are known to express all
recognised TLRs [169], however the expression of TLRs
on astrocytes is a contentious topic, with some researchers
observing the presence of TLR-2 and TLR-4 mRNA in
astrocyte culture [170], whilst others were unable to identify
the expression of any TLR in 99% pure human astrocytic
culture [171].
Many molecules may act as endogenous ligands for
TLR signaling, with evidence suggesting that the TLRs
involved most in TBI are TLR-2 and TLR-4, and that
signaling through these TLRs triggers NFκB activation and
gene transcription [12]. Whilst research on the role of
TLRs after TBI is scant, levels of TLR2 has been noted
to be signiﬁcantly upregulated after mouse bilateral corti-
cal contusion [172], and signiﬁcant inﬁltration of TLR-2
positive macrophages/microglia has been observed in the
lesioned area and subcortical white matter after weight-
drop injury in rats [173]. It appears though that the most
compelling evidence of the roles of TLRs in TBI comes from
experiments in which they are suppressed or deleted, with
TLR-2knockoutmiceshowingan18-foldreductioninGFAP
mRNA, and 4-fold reduction in CD11b mRNA after stab-
wound injury when compared to wild type. The authors
also found less inﬁltrating astrocytes in the lesioned area,
with those present possessing a less-activated morphology
[174], suggesting that activation of TLR-2 was a substantial
contributing factor to glial activation. In another study, sup-
pression of TLR-4 using the monosomic alkaloid oxymatrine
after focal TBI led to reduced gene expression of NFκBa n d
lower concentrations of TNF-α,I L - 1 β,a n dI L - 6 ,w i t hf e w e r
apoptotic neurons as a consequence, suggesting a negative
role for TLR-4 in neuroinﬂammation [175]. A double-
knockout of TLR-2 and TLR-4 also resulted in decreased IL-
1β and MCP-1 signaling after sciatic nerve damage, as well as
signiﬁcantly decreased macrophage recruitment/microglial
activation, however these rats were noted to have poor
locomotor recovery, impaired Wallerian degeneration, and
inhibited axonal regeneration [176]. Interestingly, a single
microinjection of the TLR-2 and TLR-4 ligands at the lesion
site resulted in faster clearance of degenerating myelin, and
signiﬁcant and sustained improvement in motor function,
indicating that while TLR signaling may be detrimental in
terms of the acute neuroinﬂammatory response, it may in
fact be important for long term recovery in terms of myelin
clearance and nerve regeneration [176].
14. Immunotherapies for TBI
Despite more than 30 years of research, not a single eﬀective
therapy has been developed for the treatment of TBI. A
multitude of compounds showing promise in animal studies
have failed to exhibit beneﬁcial eﬀects in clinical trials, with
more than 20 compounds reaching phase II/III trials but
showing no long-term beneﬁt [7]. In one of the largest
clinical trials for TBI to date, the corticosteroid randomisa-
tion after signiﬁcant head injury (CRASH) trial investigators
found that despite encouraging results in animal studies in
which corticosteroid treatment was found to be eﬃcacious,
inaclinicalsetting theadministration ofcorticosteroidsafter
TBI was strongly correlated with excess mortality [177].
The lack of success of clinical trials has been attributed to
several factors, including superﬁcial examination in animal
models with premature translation to the clinic, variations
in therapeutic windows in animals and humans and variable
dosing schedules, and failure of experimental models to
include secondary insults which are commonplace in clinical
TBI. Finally, animal models of TBI are by design well-
controlled and reproducible, whilst clinical TBIs are far
more complex and inherently heterogeneous [178, 179]. In
order to address these problems, experimental studies are
increasingly employing more clinically relevant species with
secondary insults, and many compounds are trialed in larger
animalmodelsinordertoestablisheﬃcacyinmoreclinically
relevant brains before moving to clinical trial. Compounds
that are currently under investigation for the treatment of
TBI fall broadly into two categories: those with multiple
targets and modes of action in CNS pathologies, and those
withasingletargetofaction.Examplesofeachwithrelevance
to innate immunity are presented below.
14.1. Compounds of Multifunctional Modality
14.1.1. Erythropoietin. Erythropoietin (Epo) is a haemato-
poietic cytokine produced mainly by the kidney which is
rapidly upregulated in response to hypoxia [180]. Epo has
been used extensively in the treatment of chronic renal and
anaemic patients and has been shown to reduce mortality
in trauma patients [181]. In recent years, Epo has been
highlighted as a promising neuroprotective candidate due
to its current clinical use with few side eﬀects and feasible
therapeutic window of ∼6h o u r s[ 182]. Epo and its receptor
EpoR are rapidly upregulated in the brain after various
insult models [183], and its administration after experi-
mental injury was shown to be eﬃcacious in a number of
experimental TBI paradigms. Importantly for the treatment
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beneﬁts including anti-inﬂammation, with a reduction in
immune mediators’ levels and subsequent reduction in
inﬂammatory cell inﬁltrates, diminished cell death, reduc-
tion of oedema, rectiﬁcation of BBB dysfunction, resolution
of cerebral vasospasm, as well as enhanced neurogenesis, and
angiogenesis and improvement in sensorimotor function
[183–187]. Currently, Epo is being investigated in a phase
III clinical trial within multiple sites in Australia, with an
estimated completion date of 2014.
14.1.2. Minocycline. The tetracycline derivative minocycline
has been posited as a neuroprotective candidate in several
experimental models of CNS injury due to its potent anti-
inﬂammatory actions [61]. After focal TBI in mice, minocy-
cline has been shown to attenuate microglial activation
and reduce the expression of IL-1β [61, 188, 189], as well
as acutely reduce the size of focal brain lesions [61, 188,
190] and decrease cerebral oedema [189]. Minocycline may
also improve neurological function, however several studies
report this eﬀect may be transient, with beneﬁcial outcomes
only observed acutely [61, 190]. Minocycline is currently
beinginvestigatedinaphaseItrialinDetroit,Michigan,with
imminent completion.
14.1.3. Progesterone. The hormone progesterone has been
shown to have multiple functions in the treatment of brain
injury, and is able to exert its eﬀects through steroidal,
neuroactive and neurosteroidal mechanisms [191]. Experi-
mentally, progesterone acts as a potent anti-inﬂammatory
agent by dampening the cytokine response and limiting
immune cell activation and extravasation [192], as well as
decreasing NFκB-mediated inﬂammatory gene transcription
[193]. Progesterone has proved to be particularly eﬀective
in the treatment of focal brain injuries, in which it has
been demonstrated to reduce neuronal damage, minimise
oedema and improve neurological outcomes in a variety of
focal contusion models [194–198]. Progesterone can also
aﬀect the complement system, with signiﬁcant reductions
in C3 cleaved fragments observed after bilateral frontal
contusion in rats [193]. Although limited in number,
studies of progesterone’s eﬀects on diﬀuse TBI have also
demonstrated beneﬁt with a reported reduction in BBB
permeability and subsequent oedema [199]a sw e l la sa
decreased number of apoptotic cells and the apoptotic
precursor caspase 3, and a substantial decline in axonal
pathology [200]. Importantly for translation to the clinic,
delaying the administration of progesterone for 24h still
resulted in beneﬁt, with a diminished oedema observed after
cortical contusion injury [201]. Due to these beneﬁts in
rodent models, progesterone has been applied clinically, with
evidence from the ProTECT clinical trial and other pilot
studies suggesting that progesterone may reduce mortality
and improve neurological outcomes after TBI [202, 203],
warranting further investigation in a large multicentre trial.
The ProTECT trial has now entered phase III, with an
estimated completion date of 2015.
14.2. Single-Target Compounds
14.2.1. Complement Inhibition. The complement system
presents as an attractive target for immune modulation
after TBI due to its prominent role in inﬂammatory cell
extravasation. Several aspects of the complement system
are amenable to interventions such as selective antagonists,
making them viable candidates for clinical translation.
Experimentally, administration of the soluble complement
receptor 1 after weight drop injury in the rat signiﬁcantly
attenuates neutrophil inﬁltration into the injured brain
[96]. A similar eﬀect on neutrophil extravasation was
also observed after cryoinjury in mice with deletion of
either the C3 or C5 gene, or administration of the C5a
receptor antagonist, with corresponding reductions in the
chemokines CCL5 and CCL2, and smaller lesions as a
consequence [88]. Inhibition of the alternative pathway has
also shown promising results, with targeted deletion of the
factorBgeneordeliveryofantifactorBneutralisingantibody
resulting in signiﬁcantly decreased C5a serum levels and a
reduction in cell apoptosis [204, 205]. Although it appears
that targeting the complement system in the acute phase
may be beneﬁcial, it may also have deleterious consequences
for long-term recovery. For example, treatment with the
C5a receptor antagonist in rats after spinal cord injury
resulted in a signiﬁcantly less macrophages/microglia in the
injury site at 7 days, however these rats also had poor
locomotor recovery and reduced myelination, suggesting
thatwhileearlyinhibitionofC5amaybebeneﬁcial,thelong-
term outcome of reducing this aspect of inﬂammation is
detrimental [206].
14.2.2. Anticytokine Antibodies. Whilst cytokines appear a
natural target for neutralisation as the perpetuators of the
inﬂammatory response, they must be considered in the
context of the whole organism, in that the beneﬁcial eﬀects
of abolishing such a targeted response may have more broad
adverse consequences in recovery. Studies suggest, however,
that there may be some beneﬁt to inhibiting the actions of
several cytokines, with neutralisation of IL-1β after focal TBI
in mice attenuating neutrophil inﬁltration and microglial
activation, minimising the number of ICAM-1 positive cells,
and reducing oedema and improving cognitive outcome
[145, 207, 208]. Treatment of mice with the IL-1ra has also
resulted in beneﬁt in various models and species, with better
behavioural scores and attenuation of oxidative stress, as well
as smaller lesion volumes [209, 210]. Importantly for the
clinic, IL-1ra is able to penetrate the BBB in concentrations
considered to be experimentally therapeutic [211], and even
when administration is delayed by 4h under experimental
conditions, smaller lesion volumes are still observed in an
animal model of TBI [210].
Therapeutic inhibition of TNF has also been demon-
strated with good result after closed head injury in rats,
with a reduction in oedema and recovery of motor function
reported [125,212].However,thiseﬀectmayvarydepending
on the model of TBI employed, with other researchers
ﬁndingnobeneﬁtwhenemployingneutralisingantibodiesto
TNFinalateralﬂuidpercussioninjuryintheratwithrespect
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after injury [213]. Results of TNF neutralisation may also
vary between species, with no eﬀe c to b s e rv e do nb e h a vi o u ra l
outcomes, lesion volumes or cell death in mice subjected to
closed head injury [214].
14.2.3. Antibodies to Cell Adhesion Molecules. Targeting the
passage of immune cells through the BBB via inhibition of
cell adhesion molecules presents an interesting avenue to
dampen the neuroinﬂammatory response to TBI. Experi-
mentally, administration of antibodies to ICAM-1 resulted
in a substantial decrease in neutrophil recruitment [55,
122], however neutrophil accumulation was not completely
abolished, thus suggesting a prominent role for other
cell adhesion molecules in the absence of ICAM-1 [55].
Neutralisation of ICAM-1 also signiﬁcantly improved motor
performance after lateral ﬂuid percussion injury in the rat,
however a signiﬁcant eﬀect was also seen with IgG injection,
indicating that there may be a nonspeciﬁc antibody eﬀect
[122]. In mice deﬁcient in ICAM-1, however, no beneﬁcial
eﬀect was observed with regard to neutrophil accumulation,
lesion volume, or motor or cognitive function [215]. In
mice double knockout mice for both ICAM-1 and P-selectin,
whilst a signiﬁcant reduction in oedema was observed,
no diﬀerences to wild type were found with regard to
histopathology,motororcognitivefunction[216],providing
more supporting evidence for a compensatory role of other
cell adhesion molecules.
15. Summary
The innate immune response plays an intrinsic role in
the governance of TBI, with both beneﬁcial and delete-
rious consequences. This response is largely mediated by
resident innate immune cells (microglia and astrocytes),
while passage of peripheral immune cells into the brain is
facilitated by opening of the BBB, or by upregulation of
adhesion molecules and chemokines to aid their movement
into the injured tissue. Chemokines such as CXCL2 and
CCL-2, and cytokines such as IL-1β, TNF, and IL-6 also
play essential roles in dictating migration and recruitment of
immune cells to sites of injury, with reparative or destructive
consequences depending on the timing of their release and
their concentrations. Whilst the intention of the innate
immune response is to promote repair, restorative eﬀorts are
often hampered by the presence of additional inﬂammatory
factors such as complement proteins and increased signaling
through microglial TLRs, which results in a disproportionate
and self-perpetuating immune response. This dysregulation
has become a key target for therapeutic intervention, with
both single-target and multifunctional drugs evaluated in
eﬀorts to curb the innate immune response. Therapeutic
targets are wide ranging, with a focus ranging from adhesion
molecules to cytokines in an eﬀort to minimise cell entry,
activation and expansion. As yet, no one compound has
proven eﬃcacious when applied in multiple models or
translated to the clinic, highlighting the need for more
rigorous investigation in multiple pathological scenarios
prior to clinical application.
16. Conclusion
It has become increasingly clear over the last two decades
that the innate immune system plays a crucial role in the
pathogenesis of TBI. The innate immune system is, by
nature, complex and interrelated, with each crucial aspect
shaping the structure for the next, and ultimately determin-
ing the outcome following TBI. It is this intricate nature,
however, which heightens the challenge faced by researchers
and clinicians alike in both understanding and combating
the secondary consequences of brain trauma. While research
into the pathogenesis of TBI is rapidly advancing, many
of the complex interactions between compartments of
the innate immune response are still unknown. However,
with further understanding and more thorough preclinical
screening of neuroprotective candidates, the development
of an eﬀective therapy for the treatment of TBI could be
achieved.
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